Analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Titan Pharmaceuticals stock opened at $3.99 on Friday. Titan Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $14.80. The business has a 50-day simple moving average of $5.32 and a two-hundred day simple moving average of $5.95.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- The Significance of Brokerage Rankings in Stock Selection
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Stock Average Calculator
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What is the Dow Jones Industrial Average (DJIA)?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
